Literature DB >> 32682983

Astragaloside IV improves neurobehavior and promotes hippocampal neurogenesis in MCAO rats though BDNF-TrkB signaling pathway.

Guang-Xiao Ni1, Ce Liang2, Jing Wang2, Chun-Qiao Duan1, Pu Wang1, Ya-Li Wang3.   

Abstract

Astragaloside IV (AST) as the main active ingredient of Astragalus membranaceus. Clinical and laboratory-based studies have demonstrated the effects of AST on cerebral protection and angiogenesis after ischemia stroke. In addition, several reports investigated the effect of AST on proliferation of neural stem cells. The current study was aimed to evaluate the influence of AST on neurogenesis in hippocampal dentate gyrus (DG) of MCAO rats and to explore the possible mechanisms. In this study, the neurobehavioral tests (Ludmila Belayev 12-point scoring, Screen test, fore limb placing test) had been employed to investigate the effect of AST treatment against functional deficit of MCAO rats. The immunofluorescence staining, western-blot and qRT-PCR was performed to evaluate the effects of AST on proliferation, differentiation and maturity of neural stemr cells in hippocampus. Moreover, we investigated the possible mechanism of the AST treatment in promoting neurogenesis after ischemic stroke. The findings indicated that AST treatment ameliorated the neurobehavior of MCAO rats. The results indicated that AST treatment possessed the potential to improve proprioceptive sense and motor function of MCAO rats. AST treatment sustained neuronal viability and stimulates sensorimotor integration functional recovery in MCAO rats. The results suggested that AST improved neurobehavior deficit after ischemic stroke. Furthermore, AST promoted neurogenesis through upregulating the expressing of BNDF/TrkB signaling pathway. Therefore AST might be a promising therapeutic agent for ischemic stroke.
Copyright © 2020 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Astragaloside IV; Hippocampus; Ischemic stroke; Neurogenesis

Mesh:

Substances:

Year:  2020        PMID: 32682983     DOI: 10.1016/j.biopha.2020.110353

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  6 in total

Review 1.  A Review of Traditional Chinese Medicine, Buyang Huanwu Decoction for the Treatment of Cerebral Small Vessel Disease.

Authors:  Liying Sun; Xuhui Ye; Linlin Wang; Junping Yu; Yan Wu; Minpeng Wang; Lihua Dai
Journal:  Front Neurosci       Date:  2022-06-29       Impact factor: 5.152

Review 2.  Traditional Chinese Medicine Monomers: Novel Strategy for Endogenous Neural Stem Cells Activation After Stroke.

Authors:  Ju Wang; Jun Hu; Xuezhu Chen; Xuejiao Lei; Hua Feng; Feng Wan; Liang Tan
Journal:  Front Cell Neurosci       Date:  2021-02-26       Impact factor: 5.505

3.  Edaravone Alleviated Propofol-Induced Neurotoxicity in Developing Hippocampus by mBDNF/TrkB/PI3K Pathway.

Authors:  Yangliang Yang; Jing Yi; Mengzhi Pan; Baoji Hu; Hongwei Duan
Journal:  Drug Des Devel Ther       Date:  2021-03-30       Impact factor: 4.162

4.  Authentication of Shenqi Fuzheng Injection via UPLC-Coupled Ion Mobility-Mass Spectrometry and Chemometrics with Kendrick Mass Defect Filter Data Mining.

Authors:  Xingdong Wu; Yaowen Liu; Zijia Zhang; Zhihuang Ou; Guoxiang Wang; Tengqian Zhang; Huali Long; Min Lei; Liangfeng Liu; Wenhua Huang; Jinjun Hou; Wanying Wu; De-An Guo
Journal:  Molecules       Date:  2022-07-24       Impact factor: 4.927

5.  Hippocampal neuroprotection mediated by secretome of human mesenchymal stem cells against experimental stroke.

Authors:  Afsaneh Asgari Taei; Leila Dargahi; Pariya Khodabakhsh; Mehdi Kadivar; Maryam Farahmandfar
Journal:  CNS Neurosci Ther       Date:  2022-06-18       Impact factor: 7.035

6.  The Cerebroprotein Hydrolysate-I Plays a Neuroprotective Effect on Cerebral Ischemic Stroke by Inhibiting MEK/ERK1/2 Signaling Pathway in Rats.

Authors:  Yuqian Ren; Xiaoqing Ma; Tingting Wang; Baohe Cheng; Leiming Ren; Zehua Dong; Hongling Liu
Journal:  Neuropsychiatr Dis Treat       Date:  2021-07-06       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.